Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 18/20 | 0.39 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.37 |
| ▸ | FABP1 | P07148 | 3/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19309611 | 0.87 | RET (0.40) | RETNR1H4HSD17B13GPBAR1 | |
| SCHEMBL17839925 | 0.86 | NR1H4 (0.37) | NR1H4HSD17B13GPBAR1FABP1FABP4 | |
| SCHEMBL9957338 | 0.84 | RET (0.43) | RETNR1H4HSD17B13GPBAR1 | |
| SCHEMBL24598908 | 0.84 | GPBAR1 (0.51) | RETNR1H4HSD17B13GPBAR1FABP1 | |
| SCHEMBL30605725 | 0.84 | GPBAR1 (0.51) | RETNR1H4HSD17B13GPBAR1FABP1 | |
| SCHEMBL17848880 | 0.82 | RET (0.42) | RETNR1H4HSD17B13GPBAR1FABP1 | |
| SCHEMBL19202559 | 0.81 | NR1H4 (0.57) | NR1H4 | |
| SCHEMBL17839459 | 0.81 | RET (0.41) | RETNR1H4HSD17B13GPBAR1 | |
| SCHEMBL19899990 | 0.81 | NR1H4 (0.49) | RETNR1H4FABP1FABP4 | |
| SCHEMBL29384878 | 0.81 | NR1H4 (0.57) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109320517-B | FXR receptor agonists | 轩竹生物科技有限公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-108064223-B | FXR (NR1H4) MODULATING COMPOUNDS CONTAINING HYDROXY GROUPS | 吉利德科学公司 | 2021-06-01 | — | — | CN | disclosed |
| EP-3233850-B1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2019-04-03 | — | — | EP | disclosed |
| EP-3233850-B1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2019-04-03 | — | — | EP | disclosed |
| US-9751874-B2 | Hydroxy containing FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751874-B2 | Hydroxy containing FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751874-B2 | Hydroxy containing FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160176861-A1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2016-06-23 | — | — | US | disclosed |
| WO-2016096115-A1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160176861-A1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160176861-A1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176861-A1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H3, NR1H2 | RET 601/4885NR1H4 1/4885HSD17B13 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.